Genetically engineered bacteria have emerged as one of the hottest topics for using these in diagnosing cancer. These modified microorganisms could change the world of cancer detection, especially in situations where early detection is necessary. The basis of the concept is to transform bacteria into “biosensors” that can detect a particular mutation or marker existing in cancer cells. This review explores the mechanisms, applications, and future of this remarkable technology based on data and insights from recent periods.

How do Genetically Engineered Bacteria Work?

The rationale behind genetically engineered bacteria is in its own ability to fundamentally interact by themselves with its environment. Some bacteria are competent in the first place, such as Acinetobacter baylyi, which can voluntarily take up extracellular DNA in their surroundings. This natural ability has been enhanced using advanced genetic tools such as CRISPR-Cas9 to recognize specific cancer-associated mutations.

For instance, researchers have successfully engineered bacteria to detect the KRAS gene mutation, which is present in approximately all cancers, including 35-45% of colorectal cancers. The engineered bacteria can bind to and incorporate DNA containing this mutation, triggering a detectable response. Laboratory experiments have used markers like antibiotic resistance or fluorescence to signal successful DNA detection, although clinical applications would require more patient-friendly outputs like changes in stool, urine, or blood tests.

Applications in Colorectal Cancer

Colorectal cancer is a prime target for this technology due to its proximity to the gut microbiota. According to the World Health Organization (WHO), colorectal cancer is the third most common cancer worldwide, with nearly 2 million new cases and over 900,000 deaths annually.

While traditional screening methods like colonoscopies are highly effective, they are invasive and often avoided. Non-invasive alternatives, like fecal immunochemical tests (FIT) and stool DNA tests, are less accurate, particularly in detecting precancerous conditions. Engineered bacteria could bridge this gap by detecting cell-free DNA (cfDNA) released directly by tumors into the intestinal lumen.

Scientists at the University of California, San Diego, recently revealed a method for engineering bacteria that identifies KRAS mutations within a mouse model, which they effectively proved in 2023. Introducing bacteria through a rectal route detected the tumor DNA efficiently compared to conventional detection techniques. This advancement is an innovative approach towards earlier diagnosis, better prognosis, and increased chances of survival for a patient.

Also Read: How Climate Change Affects The Skin Microbiome?

Advantages Over Traditional Diagnostic Tools

1. Increased Sensitivity:

Most of the conventional cancer detection tools like blood-based liquid biopsies cannot easily identify cfDNA since it is degraded. However, engineered bacteria work directly at the site of the tumor and, therefore improve detection significantly.

2. Cost-Effectiveness:

Just one genetically engineered bacteria test may replace a cluster of expensive diagnostic tests, therefore, increasing accessibility to screening for cancer.

3. Possibilities for Early Detection:

Early-stage cancers are usually asymptomatic, so they are often undiagnosed. Biosensors based on bacterial cells may detect mutation from precancerous polyps to prevent the final disastrous effect.

4. Customizability:

These bacteria can be engineered to identify various types of mutations and thus can be applied to diagnose different types of cancer.

Current Limitations and Challenges

Despite all these promises, many hurdles need to be crossed before genetically engineered bacteria can come into clinical application:

1. Safety Issues:

Introducing genetically modified organisms into the human body risks complications. Though the bacteria are genetically designed to be non-pathogenic, this requires a regulatory approval for the reduction of any unintended complications.

2. Specificity and Precision:

It is, of course, very important that engineered bacteria differentiate cancerous mutations from non-cancerous genetic variations. False positives might trigger interventions not warranted while false negatives could delay interventions appropriately.

3. Regulatory Barriers:

Medical applications involving live bacteria are heavily regulated. Preclinical and clinical trials will be very extensive to obtain approvals from bodies such as the FDA.

Also Read: Microplastics Found In Human Blood For The First Time

Expanding the Scope of Genetically Engineered Bacteria: Beyond the Gut

While colorectal cancer is an immediate focus, researchers are exploring how engineered bacteria could be adapted for other cancers. Tumors in areas with significant bacterial populations, such as the lungs or urinary tract, may benefit from similar detection systems.

In addition, scientists have been studying the use of bacteria for cancers in such sterile environments as the pancreas. If bacteria can be equipped with targeting mechanisms to identify specific tissues, their applications could be expanded.

The Future of Cancer Detection with Bacterial Biosensors

The future of genetically engineered bacteria in cancer diagnostics is bright. Scientists see a future where these biosensors will be integrated with therapeutic functions. For instance, bacteria may not only detect mutations but also deliver targeted therapies to become living drugs. Methods to make the output of detection more user-friendly are also being worked on, such as producing colorimetric changes in stool or blood samples.

As synthetic biology advances, these innovations could extend beyond cancer to other diseases where cfDNA detection is critical, such as infections or genetic disorders.

Statistical Insights

• The global prevalence of colorectal cancer thus calls for innovative solutions. The American Cancer Society reports that by 2024, some 152,810 people in the U.S. are expected to be diagnosed with colorectal cancer, and this number will result in 53,010 deaths. Early diagnosis would, therefore, significantly reduce that number.
• Studies reveal that the five-year survival rate of early-stage colorectal cancers is 90% compared to less than 14% in stage IV cancers. Thus, early diagnostic tools like bacterial biosensors would be very life-saving.

Explore detailed studies and breakthroughs at the University of California Research and Genetic Engineering News for further reading.

Conclusion

Genetically engineered bacteria are next to revolutionize the practice of detecting and treating cancer. Combining biological intuition with cutting-edge tools of genetics, researchers would open the way to diagnose safely, faster, and far more accurately. Challenges in the way, this nevertheless represents an exciting frontier within medicine.

The path to clinical application requires collaboration among researchers, clinicians, and regulators, but the ultimate goal is clear: a future where cancer is detected early and treated effectively, thanks to the tiny yet powerful allies in our microbiome.

Also Read: The Impact Of Antibiotics On Gut Microbiome Balance